Vyome Holdings, Inc. Stock Price, News & Analysis

Vyome (Nasdaq: HIND) reported positive final Phase 2 results for topical VT-1953 in malignant fungating wounds (MFW). The trial met its primary endpoint with investigator-assessed malodor improvement (P=0.002) and showed statistical improvements in patient-reported smell impact on quality of life (P=0.0256) and wound pain (P=0.002). Improvements were observed as early as Day 7 and held at Day 14 versus vehicle (primary comparison P=0.0015; pain vs vehicle P=0.0026). VT-1953 was well tolerated with no new safety concerns. Vyome plans to discuss a pivotal Phase III design with the FDA, target a 2026 pivotal start, and pursue approval to address an estimated $1B addressable market.

Vyome (NASDAQ: HIND) appointed Dr. Aditya Bardia as Senior Medical Advisor to guide clinical development of its lead asset VT-1953 for treatment of symptoms of malignant fungating wounds (MFW).

Vyome said approval for VT-1953 is being targeted in 2026. Dr. Bardia is described as having led clinical development programs that produced approvals for Sacituzumab Govitecan, Trastuzumab Deruxtecan, Datopotamab Deruxtecan and Elacestrant. Vyome called the appointment a milestone as it prepares pivotal studies and aims to design cost-efficient trials for VT-1953.

Vyome Holdings (NASDAQ: HIND) reported its first quarter as a Nasdaq-listed company, highlighting clinical, corporate and financial milestones on November 18, 2025. Interim Phase 2 data for VT-1953 showed a statistically significant reduction in malodor (P<0.001), with reported pain and quality-of-life improvements and an excellent safety profile. The company reported $5.7 million in cash and short-term investments, with an expected runway through the end of 2026. Vyome added a CTO and SVP of Clinical Development, acquired MIT startup Oculo to launch an AI strategy, and plans FDA discussions and orphan-drug activity in H1 2026.

Vyome Holdings (Nasdaq: HIND) held its annual shareholder meeting on October 28, 2025. All three Class I directors — Krishna K. Gupta, Shiladitya Sengupta, and Stash Pomichter — were re-elected to serve until the 2028 annual meeting with 93% of votes cast in favor.

Shareholders ratified Kreit & Chiu CPA LLP as the independent registered public accounting firm for fiscal 2025 and approved the 2025 Equity Incentive Plan and named executive officer compensation. Management emphasized alignment with shareholders, noting independent directors are not taking cash compensation or new equity grants except merger-issuable awards. Vyome said it remains focused on clinical-stage immuno-inflammatory assets across the US–India innovation corridor.

Vyome Holdings (NASDAQ:HIND) has announced the acquisition of Oculo, Inc., an MIT AI spinout, and launched a new business unit focused on using AI to combat inflammation. The company aims to develop an AI psychiatrist trained on US and India data to diagnose and treat systemic inflammation by targeting behavioral drivers and biomarkers.

A newly-formed AI subcommittee of MIT alumni will oversee the initiative, which aims to establish a novel therapeutic category combining mental health, psychoneuroimmunology, and digital health. The company confirms it remains fully funded through 2026 to advance its core biotech assets, with the digital therapeutics market potential estimated at over $100B in the next decade.

Vyome Holdings (NASDAQ: HIND) has strengthened its leadership team with two significant appointments. Dr. Richard Fahrner, with over 25 years of drug development experience and involvement in 17 approved medicines, joins as Chief Technology Officer. Dr. Tamara Agajanov, bringing nearly 30 years of clinical operations expertise, takes the role of Senior Vice President – Clinical Development.

The company is currently conducting a Phase 2 study in malignant fungating wounds (MFW), representing a potential multi-billion dollar market opportunity. Topline results are expected by October 2025. The appointments come at a crucial time as Vyome prepares for pivotal trial studies, with interim Phase 2 results in MFW described as "very encouraging."

Vyome Holdings (NASDAQ:HIND) has announced positive interim results from its Phase 2 proof-of-concept study of VT-1953 topical gel for treating malignant fungating wounds (MFW). The study demonstrated statistically significant improvements in the primary endpoint of reducing wound-associated malodor (P<0.001), as well as secondary endpoints including lesion pain reduction and quality of life improvement.

MFW affects 5-14% of advanced cancer patients, with an estimated 650,000 patients in the US and 10 million globally. The company estimates a $1 billion market opportunity in the United States alone. VT-1953 has shown good tolerability in over 500 patients, with no clinically significant adverse effects reported. Vyome plans to interact with the FDA in early 2026, with full results expected in October 2026.

Vyome Holdings (NASDAQ:HIND), a clinical-stage healthcare holding company, has signed a non-binding Memorandum of Understanding (MoU) with Embryyo Technologies, an Indian medical device innovation studio. The partnership aims to explore opportunities in the AI-enabled medical device market.

The collaboration combines Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to develop smart medical devices for disease management and treatment. Embryyo's portfolio includes developments in interventional oncology, surgery, wearables, and drug delivery. As part of the initiative, both companies will host a global AI-enabled medical device innovation forum focusing on the US-India corridor.

Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company, has announced a strategic review of its 70% controlling stake in Livechain Inc. (OTCID: LICH). The Board of Directors will spend the next month evaluating various options for Livechain.

The strategic alternatives under consideration include launching a new business, forming a crypto treasury, pursuing a merger, or selling the asset. Vyome initially acquired its controlling interest in LICH in 2021 with plans to establish a viable publicly traded business on the OTC market. With Vyome now trading on Nasdaq, the company is exploring new opportunities for its Livechain investment.